Skip to content

Long term lower dose of sucrose may prevent migraine

Long term Low-Dose sucrose for migraine prophylaxis among adults and college migraineurs

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16008864
Enrollment
Unknown
Registered
2016-07-21
Start date
2012-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

group of intervention of university students:sucrose 5g/day oral liquid
group of control of university students:glucose 2.5g/d
group of intervention of adults:sucrose 5g/day oral liquid
group of control of adults:fructose 2.5g/d

Sponsors

School of Public Health,Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 61 Years

Inclusion criteria

Inclusion criteria: 1. Male or female non-premonitory migraine patients between 18-65 years old; 2. Diagnosed as migraine according to the diagnostic criteria specified by the International Classification of Headache Disorder, 3rd edition (beta version) and initial of age is less than 50 years old; 3. Migraine present for at least three years and patients having 2-6 attacks per month; 4. Moderate to severe pain (VAS=3.6) which affected the work and learning; 5. No prophylactic drugs of migraine such as beta-blockerscalcium channel blockersantiepileptic drugs and son on were taken in the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Having analgesics more than 10 times due to the migraine attacks every month; 2. Special types of migraine such as ophthalmoplegia hemiplegic migraine type; 3. Cluster headache,tension-type headache and other secondary headache disorders; 4. Pregnancy and lactation women; 5. Combined with hepaticrenal hematopoietic system and other serous primary diseases, hypertension and diabetes mellitus; 6. Having severe mental disease; 7. Allergic constitution; 8. Refused to sign the consent.

Design outcomes

Primary

MeasureTime frame
attack frequency;

Secondary

MeasureTime frame
duration of each attack;fasting blood glucose;glycosylated hemoglobin.;the severity of migraine measured by VAS score during the attack.;

Countries

China

Contacts

Public ContactYashuang Zhao

Harbin Medical University

zhao_yashuang@263.net+86 0451 87502823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026